DAVOREN, Jennifer E JE,DOUNAY, Amy Beth AB,EFREMOV, Ivan V. IV,GRAY, David L. F. DLF,MENTE, Scot R. SR,ONEIL, Steven V. SV,ROGERS, Bruce N BN,SUBRAMANYAM, Chakrapani C,ZHANG, Lei L,‧達沃倫,.杜奈,.葉夫列莫夫,.格雷,.門特,.奧尼爾,.羅杰斯,SUBRAMANYAM, Chakrapani
申请号：
HK16101174.8
公开号：
HK1213256A
申请日:
2016.02.02
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing； processes for the preparation of； intermediates used in the preparation of； and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
